LIR Life Sciences Corp. BBCMF
OTC PK
| 07/31/2026 | 04/30/2026 | 01/31/2026 | 10/31/2025 | 07/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 3.60K | 4.90K | -- | -- | 7.30K |
| Gross Profit | -3.60K | -4.90K | -- | -- | -7.30K |
| SG&A Expenses | 520.20K | 860.10K | 1.34M | 140.40K | 93.80K |
| Depreciation & Amortization | -- | 900.00 | 1.00K | 1.00K | 800.00 |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 706.60K | 903.90K | 1.35M | 141.40K | 101.90K |
| Operating Income | -706.60K | -903.90K | -1.35M | -141.40K | -101.90K |
| Income Before Tax | -708.50K | -1.02M | -1.56M | -141.20K | -102.00K |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -708.50K | -1.02M | -1.56M | -141.20K | -102.00K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -708.50K | -1.02M | -1.56M | -141.20K | -102.00K |
| EBIT | -706.60K | -903.90K | -1.35M | -141.40K | -101.90K |
| EBITDA | -705.70K | -903.00K | -1.35M | -140.40K | -101.10K |
| EPS Basic | -0.02 | -0.04 | -0.06 | -0.01 | -0.01 |
| Normalized Basic EPS | -0.02 | -0.02 | -0.04 | 0.00 | 0.00 |
| EPS Diluted | -0.02 | -0.04 | -0.06 | -0.01 | -0.01 |
| Normalized Diluted EPS | -0.02 | -0.02 | -0.04 | 0.00 | 0.00 |
| Average Basic Shares Outstanding | 28.67M | 28.21M | 27.69M | 19.39M | 19.00M |
| Average Diluted Shares Outstanding | 28.67M | 28.21M | 27.69M | 19.39M | 19.00M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |